Back to search

Netherlands· NL-9f9b60880b36

Repaglinide STADA 2 mg, tabletten

A repaglinide product containing repaglinide, registered in Netherlands by Stada Arzneimittel AG. The same ATC class is registered in 19 of our 19 countries.

ATC A10BX02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRepaglinide STADA 2 mg, tablettenATCA10BX02REGISTER NO.NL-9f9b60880b36PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Repaglinide is registered in 19 of 19 countries.

Countries holding a registration under ATC A10BX02 (repaglinide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 11 of them publish a price we can compare per daily dose

Repaglinide · ATC A10BX02

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of repaglinide costs, country by country.

Normalised to the WHO defined daily dose (4 mg), the median price runs from $0.30 in France to $1.47 in Switzerland — a ×4.9 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Repaglinide · price per daily dose (4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.47
  • IT Italy$0.39
  • FR France$0.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
REPAGLINIDE
Manufacturer
Stada Arzneimittel AG
Country
Netherlands (NL)
ATC code
A10BX02
ATC class
Repaglinide
Defined daily dose
4 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    103356

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

708 interactions on record for repaglinide.

Graded by severity as the source publishes them — 18 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Repaglinide · interactions on record

708 records

  • 18 severe
  • 502 moderate
  • 41 minor
  • 145 info

Most severe, free to view

  • ClopidogrelB01AC04severe
  • GemfibrozilC10AB04severe
  • ClotrimazoleA01AB18moderate
  • CimetidineA02BA01moderate

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Repaglinide in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All repaglinide products

Authorised across Europe · EMA

The same active substance is authorised in 23 EEA countries. Names it is sold under:

  • Austria · Repaglinid Ratiopharm, Repaglinid Sandoz
  • Belgium · Repaglinide Eg
  • Bulgaria · Индорин
  • Cyprus · Theroflan
  • Czechia · Vatinid
  • Germany · Repaglinid 1 A Pharma, Repaglinid Abz
  • Denmark · Repaglinid Doc Generici
  • Spain · Repaglinida Alter, Repaglinida Aurovitas
  • Finland · Repaglinid Stada
  • France · Repaglinide Arrow Lab, Repaglinide Biogaran
  • United Kingdom (Northern Ireland) · Repaglinide, Repaglinide Rivopharm Uk
  • Greece · Theroflan
  • Croatia · Reglinid, Repaglinid Pharmas
  • Iceland · Enyglid, Novonorm
  • Italy · Glicam, Repaglinide Aurobindo
  • Liechtenstein · Repaglinide Teva
  • Luxembourg · Repaglinide Eg
  • Latvia · Repaglinide Elvim
  • Malta · Repaglinide Aurobindo
  • Norway · Enyglid, Novonorm
  • Romania · Reneos, Repaglinida Arena
  • Sweden · Repaglinid Actavis, Repaglinid Stada
  • Slovenia · Repaglinid Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fb26d699-e907-498e-90a6-debab0c255fc
GET /v1/drugs/fb26d699-e907-498e-90a6-debab0c255fc?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h103356_smpc_en.pdf",
  "strength": null,
  "atc_label": "Repaglinide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg103356",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLOXAMEER 188"
  ],
  "substances": [
    "REPAGLINIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h103356_piluk.pdf",
  "authorised_at": "2009/12/02",
  "procedure_number": "NL/H/1455/003",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "103356",
  "additional_monitoring": "N"
}

See everything about repaglinide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.